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We have assessed the interference in the AG assay under high concentration of UAG (up to 10 000 pg/ml): in this experiment, we spiked in either 20 or 200 pg/ml of AG to solutions with various concentration of UAG up to 10 000 pg/ml. The recoveries of the AG under these conditions are well within the regulatory clinical biomarker requirements (i.e. 70-130%) (4). Furthermore, in the UAG infusion experiment, our average peak plasma UAG concentration is 10 900 pg/ml. A 20% lower than expected recovery of AG at the highest concentration of UAG 10 000 pg/ml, might be indicative of a small degree of signal suppression under these conditions ( (2).
Although we value the concern expressed by Gaylinn et al., the administration of UAG does improve glycemic control in obese diabetes patients. Based on our data, the high concentration of circulating UAG appears to results in lower level of circulating AG. However, we acknowledge that the reduction of circulating AG followed by UAG infusion may not be able to fully explain the therapeutic benefit of UAG. The detailed mechanism(s) of the beneficial effects of UAG on the improvement of glycemic control warrant farther studies. Consequently, we used a cautious title to the study: does des-acyl ghrelin improve glycemic control in obese diabetic subjects by decreasing AG levels? (2) . 
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